Success Metrics

Clinical Success Rate

77.8%

Based on 7 completed trials

Completion Rate

78%(7/9)

Active Trials

1(10%)

Results Posted

43%(3 trials)

Terminated

2(20%)

Phase Distribution

Ph phase_4

60%

Ph phase_1

10%

Ph phase_2

20%

Ph phase_3

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

1(10.0%)

Phase 2Efficacy & side effects

2(20.0%)

Phase 3Large-scale testing

1(10.0%)

Phase 4Post-market surveillance

6(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(7)

Terminated(2)

Detailed Status

Completed7

Terminated2

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

77.8%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (10.0%)

Phase 22 (20.0%)

Phase 31 (10.0%)

Phase 46 (60.0%)

Trials by Status

terminated220%

recruiting110%

completed770%

Recent Activity

1 active trials

Showing 5 of 10

completedphase_2

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

NCT01744249

terminatedphase_1

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

NCT05364944

recruitingphase_2

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

NCT06505395

completedphase_4

Effects of Sandostatin LAR® in Acromegaly

NCT01424241

completedphase_4

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

NCT01278342

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT01744249Phase 2

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Completed

NCT05364944Phase 1

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Terminated

NCT06505395Phase 2

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Recruiting

NCT01424241Phase 4

Effects of Sandostatin LAR® in Acromegaly

Completed

NCT01278342Phase 4

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients

Completed

NCT01618513Phase 4

Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target

Completed

NCT00076362Phase 4

Pediatric Hypothalamic Obesity

Completed

NCT00068029Phase 4

Pegvisomant And Sandostatin LAR Combination Study

Completed

NCT00068042Phase 4

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly